Shams S, Martinez JM, Dawson JRD, et al. The Therapeutic Panorama of Rheumatoid Arthritis: present state and future instructions. Entrance Pharmacol. 2021;12:680043. https://doi.org/10.3389/fphar.2021.680043. Revealed 2021 Might 28.
McInnes IB, Schett G. Pathogenetic insights from the remedy of rheumatoid arthritis. Lancet. 2017;389(10086):2328–37. https://doi.org/10.1016/S0140-6736(17)31472-1
Aletaha D, Smolen JS. Analysis and administration of rheumatoid arthritis: a assessment. JAMA. 2018;320(13):1360–72. https://doi.org/10.1001/jama.2018.13103
Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: current advances on its etiology, function of cytokines and pharmacotherapy. Biomed Pharmacother. 2017;92:615–33. https://doi.org/10.1016/j.biopha.2017.05.055
Wang Q, Qin X, Fang J, Solar X. Nanomedicines for the remedy of rheumatoid arthritis: state of artwork and potential therapeutic methods. Acta Pharm Sin B. 2021;11(5):1158–74. https://doi.org/10.1016/j.apsb.2021.03.013
Kondo Y, Yokosawa M, Kaneko S, et al. Evaluate: transcriptional regulation of CD4 + T-Cell differentiation in experimentally Induced Arthritis and Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(5):653–61. https://doi.org/10.1002/artwork.40398
Matsuo Y, Saito T, Yamamoto A, Kohsaka H. Origins of fibroblasts in rheumatoid synovial tissues: implications from organ fibrotic fashions. Mod Rheumatol. 2018;28(4):579–82. https://doi.org/10.1080/14397595.2017.1386837
Chuang SY, Lin CH, Huang TH, Fang JY. Lipid-Primarily based Nanoparticles as a Potential Supply Strategy within the Therapy of Rheumatoid Arthritis. Nanomaterials (Basel). 2018;8(1):42. Revealed 2018 Jan 15. doi:https://doi.org/10.3390/nano8010042
Guo L, Zhong S, Liu P, Guo M, Ding J, Zhou W. Radicals scavenging MOFs enabling concentrating on supply of siRNA for rheumatoid arthritis remedy. Small. 2022;18(27):e2202604. https://doi.org/10.1002/smll.202202604
Yang Y, Guo L, Wang Z, et al. Focused silver nanoparticles for rheumatoid arthritis remedy through macrophage apoptosis and repolarization. Biomaterials. 2021;264:120390. https://doi.org/10.1016/j.biomaterials.2020.120390
Chen SJ, Lin GJ, Chen JW et al. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. Int J Mol Sci. 2019;20(6):1332. Revealed 2019 Mar 16. doi:https://doi.org/10.3390/ijms20061332
Araki Y, Mimura T. Matrix Metalloproteinase Gene Activation ensuing from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. Int J Mol Sci. 2017;18(5):905. https://doi.org/10.3390/ijms18050905. Revealed 2017 Apr 25.
Arioka M, Takahashi-Yanaga F. Glycogen synthase kinase-3 inhibitor as a multitargeting anti-rheumatoid drug. Biochem Pharmacol. 2019;165:207–13. https://doi.org/10.1016/j.bcp.2019.02.020
Tanaka S, Tanaka Y, Ishiguro N, Yamanaka H, Takeuchi T. RANKL: a therapeutic goal for bone destruction in rheumatoid arthritis. Mod Rheumatol. 2018;28(1):9–16. https://doi.org/10.1080/14397595.2017.1369491
Küçükdeveci AA. Nonpharmacological remedy in established rheumatoid arthritis. Finest Pract Res Clin Rheumatol. 2019;33(5):101482. https://doi.org/10.1016/j.berh.2019.101482
Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Present therapeutic choices within the remedy of rheumatoid arthritis. J Clin Med. 2019;8(7):938. https://doi.org/10.3390/jcm8070938. Revealed 2019 Jun 28.
Xu XL, Lu KJ, Yao XQ, Ying XY, Du YZ. Stimuli-responsive drug Supply Programs as an rising platform for remedy of rheumatoid arthritis. Curr Pharm Des. 2019;25(2):155–65. https://doi.org/10.2174/1381612825666190321104424
Zhou S, Zou H, Chen G, Huang G. Synthesis and Organic Actions of Chemical medication for the remedy of rheumatoid arthritis. Prime Curr Chem (Cham). 2019;377(5):28. https://doi.org/10.1007/s41061-019-0252-5. Revealed 2019 Sep 28.
Bedoui Y, Guillot X, Sélambarom J et al. Methotrexate an Outdated Drug with New Tips. Int J Mol Sci. 2019;20(20):5023. Revealed 2019 Oct 10. doi:https://doi.org/10.3390/ijms20205023
Guo L, Chen Y, Wang T, et al. Rational design of metal-organic frameworks to ship methotrexate for focused rheumatoid arthritis remedy. J Management Launch. 2021;330:119–31. https://doi.org/10.1016/j.jconrel.2020.10.069
Dogra A, Sharma A, Kumar Mandal U, Kotwal P, Bhatt S, Nandi U. Liquid chromatography based mostly strategies for evaluation of Illness-Modifying antirheumatic medication (DMARDs) in Organic Matrices. Crit Rev Anal Chem. 2019;49(3):224–42. https://doi.org/10.1080/10408347.2018.1503943
Braun J, Baraliakos X, Westhoff T. Nonsteroidal anti-inflammatory medication and cardiovascular danger – a matter of indication. Semin Arthritis Rheum. 2020;50(2):285–8. https://doi.org/10.1016/j.semarthrit.2019.07.012
Buttgereit F. Views on glucocorticoid remedy in rheumatology: the age of convergence. Nat Rev Rheumatol. 2020;16(4):239–46. https://doi.org/10.1038/s41584-020-0370-z
Xiao Q, Li X, Li Y, et al. Organic drug and drug delivery-mediated immunotherapy. Acta Pharm Sin B. 2021;11(4):941–60. https://doi.org/10.1016/j.apsb.2020.12.018
Kesharwani D, Paliwal R, Satapathy T, Das Paul S. Rheumatiod Arthritis: an up to date overview of newest remedy and drug supply. J Pharmacopunct. 2019;22(4):210–24. https://doi.org/10.3831/KPI.2019.22.029
Jang DI, Lee AH, Shin HY, et al. The function of Tumor necrosis issue alpha (TNF-α) in Autoimmune Illness and present TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. https://doi.org/10.3390/ijms22052719. Revealed 2021 Mar 8.
Lin YJ, Anzaghe M, Schülke S. Replace on the Pathomechanism, analysis, and Therapy Choices for Rheumatoid Arthritis. Cells. 2020;9(4):880. https://doi.org/10.3390/cells9040880. Revealed 2020 Apr 3.
Marahleh A, Kitaura H, Ohori F, et al. TNF-α instantly enhances osteocyte RANKL expression and promotes osteoclast formation. Entrance Immunol. 2019;10:2925. https://doi.org/10.3389/fimmu.2019.02925. Revealed 2019 Dec 13.
Lim H, Lee SH, Lee HT et al. Structural Biology of the TNFα Antagonists Used within the Therapy of Rheumatoid Arthritis. Int J Mol Sci. 2018;19(3):768. Revealed 2018 Mar 7. doi:https://doi.org/10.3390/ijms19030768
Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Present therapeutic choices within the remedy of rheumatoid arthritis. J Clin Med. 2019;8(7):938. https://doi.org/10.3390/jcm8070938. Revealed 2019 Jun 28.
Zhao S, Mysler E, Moots RJ. Etanercept for the remedy of rheumatoid arthritis. Immunotherapy. 2018;10(6):433–45. https://doi.org/10.2217/imt-2017-0155
Chen SJ, Lin GJ, Chen JW et al. Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis. Int J Mol Sci. 2019;20(6):1332. Revealed 2019 Mar 16. doi:https://doi.org/10.3390/ijms20061332
Dervieux T, Kremer JM, Weinblatt ME. Differing contribution of methotrexate polyglutamates to adalimumab blood ranges as in contrast with etanercept. Ann Rheum Dis. 2019;78(9):1285–6. https://doi.org/10.1136/annrheumdis-2018-214860
Brassard P, Kezouh A, Suissa S. Antirheumatic medication and the danger of tuberculosis. Clin Infect Dis. 2006;43(6):717–22. https://doi.org/10.1086/506935
Abbasi M, Mousavi MJ, Jamalzehi S, et al. Methods towards rheumatoid arthritis remedy; the outdated and the brand new. J Cell Physiol. 2019;234(7):10018–31. https://doi.org/10.1002/jcp.27860
Watanabe A, Matsumoto T, Igari H, Sawa J, Yamaguchi Y, Sakatani M. Danger of creating energetic tuberculosis in rheumatoid arthritis sufferers on adalimumab in Japan. Int J Tuberc Lung Dis. 2016;20(1):101–8. https://doi.org/10.5588/ijtld.15.0283
Deeks ED. Certolizumab Pegol: A Evaluate in Inflammatory Autoimmune Illnesses. BioDrugs. 2016;30(6):607–17. https://doi.org/10.1007/s40259-016-0197-y
Curtis JR, Mariette X, Gaujoux-Viala C, et al. Lengthy-term security of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s illness: a pooled evaluation of 11 317 sufferers throughout medical trials. RMD Open. 2019;5(1):e000942. https://doi.org/10.1136/rmdopen-2019-000942. Revealed 2019 Might 31.
Pelechas E, Voulgari PV, Drosos AA. Golimumab for Rheumatoid Arthritis. J Clin Med. 2019;8(3):387. https://doi.org/10.3390/jcm8030387. Revealed 2019 Mar 20.
Singh S, Facciorusso A, Singh AG et al. Weight problems and response to antitumor necrosis factor-α brokers in sufferers with choose immune-mediated inflammatory illnesses: A scientific assessment and meta-analysis [published correction appears in PLoS One. 2018 Aug 29;13(8):e0203499]. PLoS One. 2018;13(5):e0195123. Revealed 2018 Might 17. doi:https://doi.org/10.1371/journal.pone.0195123
Striz I. Cytokines of the IL-1 household: acknowledged targets in persistent irritation underrated in organ transplantations. Clin Sci (Lond). 2017;131(17):2241–56. https://doi.org/10.1042/CS20170098. Revealed 2017 Aug 10.
Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and associated cytokines within the regulation of irritation and immunity. Immunity. 2019;50(4):778–95. https://doi.org/10.1016/j.immuni.2019.03.012
Ramírez J, Cañete JD. Anakinra for the remedy of rheumatoid arthritis: a security analysis. Professional Opin Drug Saf. 2018;17(7):727–32. https://doi.org/10.1080/14740338.2018.1486819
Tarp S, Furst DE, Dossing A, et al. Defining the optimum organic monotherapy in rheumatoid arthritis: a scientific assessment and meta-analysis of randomized trials. Semin Arthritis Rheum. 2017;46(6):699–708. https://doi.org/10.1016/j.semarthrit.2016.09.003
Lopalco G, Rigante D, Cantarini L, et al. The autoinflammatory facet of recurrent pericarditis: enlightening the pathogenesis for a extra rational remedy. Developments Cardiovasc Med. 2021;31(5):265–74. https://doi.org/10.1016/j.tcm.2020.04.006
Khayata M, Shah NP, Verma BR, et al. Usefulness of Interleukin-1 receptor antagonists in sufferers with recurrent Pericarditis. Am J Cardiol. 2020;127:184–90. https://doi.org/10.1016/j.amjcard.2020.03.041
Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in youngsters and adults with nonetheless’s illness. Rheumatology (Oxford). 2019;58(Suppl 6):vi9–vi22. https://doi.org/10.1093/rheumatology/kez350
Zhou S, Qiao J, Bai J, Wu Y, Fang H. Organic remedy of conventional therapy-resistant adult-onset nonetheless’s illness: an evidence-based assessment. Ther Clin Danger Manag. 2018;14:167–71. https://doi.org/10.2147/TCRM.S155488. Revealed 2018 Jan 24.
Chatzidionysiou Ok, Circiumaru A, Rethi B, et al. Tocilizumab decreases T cells however not macrophages within the synovium of sufferers with rheumatoid arthritis whereas it will increase the degrees of serum interleukin-6 and RANKL. RMD Open. 2021;7(2):e001662. https://doi.org/10.1136/rmdopen-2021-001662
Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key participant in systemic irritation and joint destruction. Autoimmun Rev. 2009;8(7):538–42. https://doi.org/10.1016/j.autrev.2009.01.012
Scott LJ, Tocilizumab. A Evaluate in Rheumatoid Arthritis [published correction appears in Drugs. 2017 Dec 19;:]. Medicine. 2017;77(17):1865–1879. doi:https://doi.org/10.1007/s40265-017-0829-7
Cappelli LC, Palmer JL, Kremer J, Bingham CO 3. Tocilizumab remedy results in enchancment in illness exercise no matter CCP standing in rheumatoid arthritis. Semin Arthritis Rheum. 2017;47(2):165–9. https://doi.org/10.1016/j.semarthrit.2017.03.024
Morel J, Constantin A, Baron G, et al. Danger elements for severe infections in sufferers with rheumatoid arthritis handled with tocilizumab within the French Registry REGATE. Rheumatology (Oxford). 2017;56(10):1746–54. https://doi.org/10.1093/rheumatology/kex238
Kim SC, Solomon DH, Rogers JR, et al. No distinction in cardiovascular danger of tocilizumab versus abatacept for rheumatoid arthritis: a multidatabase cohort research. Semin Arthritis Rheum. 2018;48(3):399–405. https://doi.org/10.1016/j.semarthrit.2018.03.012
Ogata A, Kato Y, Higa S, Yoshizaki Ok. IL-6 inhibitor for the remedy of rheumatoid arthritis: a complete assessment. Mod Rheumatol. 2019;29(2):258–67. https://doi.org/10.1080/14397595.2018.1546357
Ahmadzadeh A, Farahmand AN, Gachkar L. Analysis of security, efficacy and postcessation efficacy sturdiness of tocilizumab in sufferers with energetic rheumatoid arthritis. Int J Rheum Dis. 2017;20(2):231–7. https://doi.org/10.1111/1756-185X.12686
Lamb YN, Deeks ED, Sarilumab. A assessment in average to extreme rheumatoid arthritis. Medicine. 2018;78(9):929–40. https://doi.org/10.1007/s40265-018-0929-z
Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential within the remedy of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–603. https://doi.org/10.2147/DDDT.S100302. Revealed 2017 Might 24.
Aly AM, Furst DE. Replace of sarilumb to deal with rheumatoid arthritis based mostly on randomized medical trials: a scientific assessment. Professional Rev Clin Immunol. 2017;13(8):741–52. https://doi.org/10.1080/1744666X.2017.1351297
June RR, Olsen NJ. Room for extra IL-6 blockade? Sarilumab for the remedy of rheumatoid arthritis. Professional Opin Biol Ther. 2016;16(10):1303–9. https://doi.org/10.1080/14712598.2016.1217988
Scott LJ, Sarilumab. First World approval. Medicine. 2017;77(6):705–12. https://doi.org/10.1007/s40265-017-0724-2
McCarty D, Robinson A. Efficacy and security of sarilumab in sufferers with energetic rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(3):61–7. https://doi.org/10.1177/1759720X17752037
Atzeni F, Nucera V, Masala IF, Sarzi-Puttini P, Bonitta G. Il-6 involvement in ache, fatigue and temper issues in rheumatoid arthritis and the results of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149:104402. https://doi.org/10.1016/j.phrs.2019.104402
Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the remedy of rheumatoid arthritis. Professional Rev Clin Immunol. 2019;15(4):319–26. https://doi.org/10.1080/1744666X.2019.1579642
Blair HA, Deeks ED, Abatacept. A assessment in rheumatoid arthritis. Medicine. 2017;77(11):1221–33. https://doi.org/10.1007/s40265-017-0775-4
Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces ranges of switched reminiscence B cells, autoantibodies, and immunoglobulins in sufferers with rheumatoid arthritis. J Rheumatol. 2014;41(4):666–72. https://doi.org/10.3899/jrheum.130905
Correction. Abatacept together with methotrexate in Japanese biologic-naive sufferers with energetic rheumatoid arthritis: a randomized placebo-controlled part IV research. RMD Open. 2019;5(2):e000813corr1. Revealed 2019 Dec 5. doi:https://doi.org/10.1136/rmdopen-2018-000813corr1
Abbasi M, Mousavi MJ, Jamalzehi S, et al. Methods towards rheumatoid arthritis remedy; the outdated and the brand new. J Cell Physiol. 2019;234(7):10018–31. https://doi.org/10.1002/jcp.27860
Mochizuki T, Ikari Ok, Yano Ok, Sato M, Okazaki Ok. Lengthy-term deterioration of interstitial lung illness in sufferers with rheumatoid arthritis handled with abatacept. Mod Rheumatol. 2019;29(3):413–7. https://doi.org/10.1080/14397595.2018.1481566
Ozen G, Pedro S, Schumacher R, Simon TA, Michaud Ok. Security of abatacept in contrast with different biologic and traditional artificial disease-modifying antirheumatic medication in sufferers with rheumatoid arthritis: information from an observational research. Arthritis Res Ther. 2019;21(1):141. https://doi.org/10.1186/s13075-019-1921-z. Revealed 2019 Jun 7.
Hofmann Ok, Clauder AK, Manz RA. Concentrating on B cells and plasma cells in Autoimmune Illnesses. Entrance Immunol. 2018;9:835. https://doi.org/10.3389/fimmu.2018.00835. Revealed 2018 Apr 23.
Singh A, Behl T, Sehgal A, et al. Mechanistic insights into the function of B cells in rheumatoid arthritis. Int Immunopharmacol. 2021;99:108078. https://doi.org/10.1016/j.intimp.2021.108078
Bryl E. B cells as goal for immunotherapy in rheumatic illnesses – present standing. Immunol Lett. 2021;236:12–9. https://doi.org/10.1016/j.imlet.2021.05.006
Kaegi C, Wuest B, Schreiner J, et al. Systematic Evaluate of Security and Efficacy of Rituximab in Treating Immune-Mediated Problems. Entrance Immunol. 2019;10. Revealed 2019 Sep 6. https://doi.org/10.3389/fimmu.2019.01990
Rath E, Zwerina J, Oppl B, Nell-Duxneuner V. Efficacy and security of rituximab in rheumatic illnesses. Wien Med Wochenschr. 2015;165(1–2):28–35. https://doi.org/10.1007/s10354-014-0331-8
Shi Y, Wu Y, Ren Y, Jiang Y, Chen Y. An infection dangers of rituximab versus nonrituximab remedy for rheumatoid arthritis: a scientific assessment and meta-analysis. Int J Rheum Dis. 2019;22(8):1361–70. https://doi.org/10.1111/1756-185X.13596
Vikse J, Jonsdottir Ok, Kvaløy JT, Wildhagen Ok, Omdal R. Tolerability and security of long-term rituximab remedy in systemic inflammatory and autoimmune illnesses. Rheumatol Int. 2019;39(6):1083–90. https://doi.org/10.1007/s00296-019-04272-1
Wang KC, Liao HT, Chen WS, et al. Actual-world effectiveness and security of rituximab within the remedy of rheumatoid arthritis: a single-center expertise in Taiwan. Int J Rheum Dis. 2019;22(5):860–8. https://doi.org/10.1111/1756-185X.13511
Jung YS, Park W, Na Ok. Temperature-modulated noncovalent interplay controllable complicated for the long-term supply of etanercept to deal with rheumatoid arthritis. J Management Launch. 2013;171(2):143–51. https://doi.org/10.1016/j.jconrel.2013.07.012
Cao J, Zhang N, Wang Z, et al. Microneedle-Assisted transdermal supply of Etanercept for Rheumatoid Arthritis Therapy. Pharmaceutics. 2019;11(5):235. https://doi.org/10.3390/pharmaceutics11050235. Revealed 2019 Might 15.
Giulbudagian M, Yealland G, Hönzke S et al. Breaking the Barrier – Potent Anti-Inflammatory Exercise following Environment friendly Topical Supply of Etanercept utilizing Thermoresponsive Nanogels. Theranostics. 2018;8(2):450–463. Revealed 2018 Jan 1. doi:https://doi.org/10.7150/thno.21668
Erdemli Ö, Özen S, Keskin D, et al. In vitro analysis of results of sustained anti-TNF launch from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. J Biomater Appl. 2014;29(4):524–42. https://doi.org/10.1177/0885328214535958
Shen Ok, Solar G, Chan L, et al. Anti-inflammatory nanotherapeutics by concentrating on Matrix Metalloproteinases for Immunotherapy of spinal twine Harm. Small. 2021;17(41):e2102102. https://doi.org/10.1002/smll.202102102
Campos Y, Fuentes G, Almirall A et al. The Incorporation of Etanercept right into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue. Pharmaceutics. 2022;14(2):282. Revealed 2022 Jan 26. doi:https://doi.org/10.3390/pharmaceutics14020282
Ferreira M, Barreiros L, Segundo MA, et al. Topical codelivery of methotrexate and etanercept utilizing lipid nanoparticles: a focused method for psoriasis administration. Colloids Surf B Biointerfaces. 2017;159:23–9. https://doi.org/10.1016/j.colsurfb.2017.07.080
Solar G, Yang S, Cai H, et al. Molybdenum disulfide nanoflowers mediated anti-inflammation macrophage modulation for spinal twine damage remedy. J Colloid Interface Sci. 2019;549:50–62. https://doi.org/10.1016/j.jcis.2019.04.047
Pabari RM, Tambuwala MM, Lajczak-McGinley N, et al. Novel polyurethane based mostly particulate formulations of infliximab scale back irritation in DSS induced murine mannequin of colitis – A preliminary research. Int J Pharm. 2021;604:120717. https://doi.org/10.1016/j.ijpharm.2021.120717
Rodríguez-Prieto T, Hernández-Breijo B, Ortega MA, Gómez R, Sánchez-Nieves J, Guijarro LG. Dendritic nanotheranostic for the supply of Infliximab: a possible provider in Rheumatoid Arthritis Remedy. Int J Mol Sci. 2020;21(23):9101. https://doi.org/10.3390/ijms21239101. Revealed 2020 Nov 30.
Li X, Yu M, Zhu Z, et al. Oral supply of infliximab utilizing nanoin-microparticles for the remedy of inflammatory bowel illness. Carbohydr Polym. 2021;273:118556. https://doi.org/10.1016/j.carbpol.2021.118556
Chen W, Li Z, Wang Z, Gao H, Ding J, He Z. Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel alleviates Ache and protects cartilage in rheumatoid arthritis. J Ache Res. 2020;13:3315–29. https://doi.org/10.2147/JPR.S283518. Revealed 2020 Dec 7.
Likhitpanichkul M, Kim Y, Torre OM, et al. Fibrin-genipin annulus fibrosus sealant as a supply system for anti-TNFα drug. Backbone J. 2015;15(9):2045–54. https://doi.org/10.1016/j.spinee.2015.04.026
Gokhale KS, Jonnalagadda S. Preparation and analysis of sustained launch infliximab microspheres. PDA J Pharm Sci Technol. 2013;67(3):255–66. https://doi.org/10.5731/pdajpst.2013.00919
Kim JM, Kim DH, Park HJ et al. Nanocomposites-based focused oral drug supply techniques with infliximab in a murine colitis mannequin. J Nanobiotechnology. 2020;18(1):133. Revealed 2020 Sep 15. doi:https://doi.org/10.1186/s12951-020-00693-4
Zhang R, Qian J, Li X, Yuan Y. Therapy of experimental autoimmune uveoretinitis with intravitreal injection of infliximab encapsulated in liposomes. Br J Ophthalmol. 2017;101(12):1731–8. https://doi.org/10.1136/bjophthalmol-2016-310044
Wang X, Yan J, Wang L, et al. Oral supply of anti-TNF antibody shielded by pure polyphenol-mediated supramolecular meeting for inflammatory bowel illness remedy. Theranostics. 2020;10(23):10808–22. https://doi.org/10.7150/thno.47601. Revealed 2020 Aug 29.
Ries M, Moulari B, Shetab Boushehri MA et al. Adalimumab Embellished Nanoparticles Improve Antibody Stability and Therapeutic End result in Epithelial Colitis Concentrating on. Pharmaceutics. 2022;14(2):352. Revealed 2022 Feb 2. doi:https://doi.org/10.3390/pharmaceutics14020352
Barnes T, Moots R. Concentrating on nanomedicines within the remedy of rheumatoid arthritis: give attention to certolizumab pegol. Int J Nanomedicine. 2007;2(1):3–7. https://doi.org/10.2147/nano.2007.2.1.3
Fernandes JC, Wang H, Jreyssaty C, et al. Bone-protective results of nonviral gene remedy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther. 2008;16(7):1243–51. https://doi.org/10.1038/mt.2008.99
Cao J, Cheng J, Xi S, Qi X, Shen S, Ge Y. Alginate/chitosan microcapsules for in situ supply of the protein, interleukin-1 receptor antagonist (IL-1Ra), for the remedy of dextran sulfate sodium (DSS)-induced colitis in a mouse mannequin. Eur J Pharm Biopharm. 2019;137:112–21. https://doi.org/10.1016/j.ejpb.2019.02.011
Whitmire RE, Wilson DS, Singh A, Levenston ME, Murthy N, García AJ. Self-assembling nanoparticles for intra-articular supply of anti-inflammatory proteins. Biomaterials. 2012;33(30):7665–75. https://doi.org/10.1016/j.biomaterials.2012.06.101
Ren B, Lu J, Li M, et al. Anti-inflammatory impact of IL-1ra-loaded dextran/PLGA microspheres on Porphyromonas gingivalis lipopolysaccharide-stimulated macrophages in vitro and in vivo in a rat mannequin of periodontitis. Biomed Pharmacother. 2021;134:111171. https://doi.org/10.1016/j.biopha.2020.111171
Liu M, Huang Y, Hu L et al. Selective supply of interleukine-1 receptor antagonist to infected joint by albumin fusion. BMC Biotechnol. 2012;12:68. Revealed 2012 Sep 25. doi:https://doi.org/10.1186/1472-6750-12-68
Clements AEB, Groves ER, Chamberlain CS, Vanderby R, Murphy WL. Microparticles regionally ship energetic Interleukin-1 receptor antagonist in vivo. Adv Healthc Mater. 2018;7(16):e1800263. https://doi.org/10.1002/adhm.201800263
Lee H, Lee MY, Bhang SH, et al. Hyaluronate-gold nanoparticle/tocilizumab complicated for the remedy of rheumatoid arthritis. ACS Nano. 2014;8(5):4790–8. https://doi.org/10.1021/nn500685h
Wang Q, Solar X. Latest advances in nanomedicines for the remedy of rheumatoid arthritis. Biomater Sci. 2017;5(8):1407–20. https://doi.org/10.1039/c7bm00254h
Bisker G, Yeheskely Hayon D, Minai L, Yelin D. Managed launch of Rituximab from gold nanoparticles for phototherapy of malignant cells. J Management Launch. 2012;162(2):303–9. https://doi.org/10.1016/j.jconrel.2012.06.030
Kim Y, Youn YS, Oh KT, Kim D, Lee ES. Tumor-targeting liposomes with transient holes permitting Intact Rituximab internally. Biomacromolecules. 2021;22(2):723–31. https://doi.org/10.1021/acs.biomac.0c01514
Li H, Guo Ok, Wu C, et al. Managed and focused drug supply by a UV-responsive Liposome for overcoming chemo-resistance in Non-Hodgkin Lymphoma. Chem Biol Drug Des. 2015;86(4):783–94. https://doi.org/10.1111/cbdd.12551
Saesoo S, Sathornsumetee S, Anekwiang P, et al. Characterization of liposome-containing SPIONs conjugated with anti-CD20 developed as a novel theranostic agent for central nervous system lymphoma. Colloids Surf B Biointerfaces. 2018;161:497–507. https://doi.org/10.1016/j.colsurfb.2017.11.003
Yin H, Meng T, Shu L, et al. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as sensible and intuitive drug supply techniques for the remedy of non-hodgkin’s lymphoma. Chem Biol Drug Des. 2017;90(5):892–9. https://doi.org/10.1111/cbdd.13010
Feng X, Chen Y. Drug supply targets and techniques for focused remedy of rheumatoid arthritis. J Drug Goal. 2018;26(10):845–57. https://doi.org/10.1080/1061186X.2018.1433680
Zeng L, Geng H, Gu W, et al. Au nanoparticles attenuate RANKL-Induced Osteoclastogenesis by suppressing Pre-Osteoclast Fusion. J Nanosci Nanotechnol. 2019;19(4):2166–73. https://doi.org/10.1166/jnn.2019.15764
Pirmardvand Chegini S, Varshosaz J, Taymouri S. Latest approaches for focused drug supply in rheumatoid arthritis analysis and remedy. Artif Cells Nanomed Biotechnol. 2018;46(sup2):502–14. https://doi.org/10.1080/21691401.2018.1460373
Koushki Ok, Keshavarz Shahbaz S, Keshavarz M, Bezsonov EE, Sathyapalan T, Sahebkar A. Gold nanoparticles: multifaceted roles within the administration of Autoimmune Problems. Biomolecules. 2021;11(9):1289. https://doi.org/10.3390/biom11091289. Revealed 2021 Aug 30.
Shahen SM, Mohamed MR, Ali MRK, Samaka RM, Hamdy GM, Talaat RM. Therapeutic potential of targeted-gold nanospheres on collagen-induced arthritis in rats. Clin Exp Pharmacol Physiol. 2021;48(10):1346–57. https://doi.org/10.1111/1440-1681.13531
Zhao P, Wang Y, Wu A, Rao Y, Huang Y. Roles of albumin-binding proteins in Most cancers Development and Biomimetic focused drug supply. ChemBioChem. 2018;19(17):1796–805. https://doi.org/10.1002/cbic.201800201
Zhong J, Zhang Q, Zhang Z et al. Albumin mediated reactive oxygen species scavenging and focused supply of methotrexate for rheumatoid arthritis remedy.Nano Analysis.2021,15(1):153–161. doi:https://doi.org/10.1007/s12274-021-3449-1
Liu L, Hu F, Wang H, et al. Secreted protein acidic and wealthy in cysteine mediated Biomimetic Supply of Methotrexate by Albumin-Primarily based nanomedicines for rheumatoid arthritis remedy. ACS Nano. 2019;13(5):5036–48. https://doi.org/10.1021/acsnano.9b01710
Zheng X, Yu X, Wang C, et al. Focused codelivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis remedy. Drug Deliv. 2022;29(1):1025–37. https://doi.org/10.1080/10717544.2022.2057616
Yan F, Li H, Zhong Z, et al. Co-Supply of Prednisolone and Curcumin in Human serum albumin nanoparticles for efficient remedy of rheumatoid arthritis. Int J Nanomedicine. 2019;14:9113–25. https://doi.org/10.2147/IJN.S219413. Revealed 2019 Nov 22.
Martinho N, Florindo H, Silva L, Brocchini S, Zloh M, Barata T. Molecular modeling to review dendrimers for Biomedical Functions. Molecules. 2014;19(12):20424–67. https://doi.org/10.3390/molecules191220424. Revealed 2014 Dec 8.
Oliveira IM, Gonçalves C, Oliveira EP, et al. PAMAM dendrimers functionalised with an anti-TNF α antibody and chondroitin sulphate for remedy of rheumatoid arthritis. Mater Sci Eng C Mater Biol Appl. 2021;121:111845. https://doi.org/10.1016/j.msec.2020.111845
Hajebi S, Rabiee N, Bagherzadeh M, et al. Stimulus-responsive polymeric nanogels as sensible drug supply techniques. Acta Biomater. 2019;92:1–18. https://doi.org/10.1016/j.actbio.2019.05.018
Preman NK, Barki RR, Vijayan A, Sanjeeva SG, Johnson RP. Latest developments in stimuli-responsive polymer nanogels for drug supply and diagnostics: a assessment. Eur J Pharm Biopharm. 2020;157:121–53. https://doi.org/10.1016/j.ejpb.2020.10.009
Samah NA, Williams N, Heard CM. Nanogel particulates situated inside diffusion cell receptor phases following topical utility demonstrates uptake into and migration throughout pores and skin. Int J Pharm. 2010;401(1–2):72–8. https://doi.org/10.1016/j.ijpharm.2010.08.011
Wang Q, Solar X. Latest advances in nanomedicines for the remedy of rheumatoid arthritis. Biomater Sci. 2017;5(8):1407–20. https://doi.org/10.1039/c7bm00254h
Nguyen Dung HT, Nguyen Ngoc B, Nguyen Linh TP et al. An Agarose–Curdlan Nanogel that Carries Etanercept to Goal and Neutralizes TNF-α Produced by Dectin-1-Expressing Immune Cells. J Elec Mater. 2019;48(10):6570–6582. https://doi.org/10.1007/s11664-019-07458-2
Walsh L, Ryu J, Bock S, et al. Nanotopography facilitates in vivo transdermal supply of excessive molecular weight therapeutics via an integrin-dependent mechanism. Nano Lett. 2015;15(4):2434–41. https://doi.org/10.1021/nl504829f
Yu HH, Fan JL, Shehla NZ, et al. Biomimetic Hybrid membrane-coated Xuetongsu assisted with laser irradiation for environment friendly rheumatoid arthritis remedy. ACS Nano. 2022;16(1):502–21. https://doi.org/10.1021/acsnano.1c07556
Qiu S, Wu XN, Li Z, et al. A Good Nanoreactor based mostly on an O2-Economized Twin Vitality Inhibition Technique Armed with Twin Multistimuli-Responsive “Doorkeepers” for enhanced CDT/PTT of Rheumatoid Arthritis. ACS Nano. 2022;16(10):17062–79. https://doi.org/10.1021/acsnano.2c07338
Pandey S, Kumar V, Leekha A, et al. Co-Supply of Teriflunomide and Methotrexate from Hydroxyapatite Nanoparticles for the remedy of rheumatoid arthritis: in Vitro characterization, pharmacodynamic and biochemical investigations. Pharm Res. 2018;35(11):201. https://doi.org/10.1007/s11095-018-2478-2
Choe JY, Prodanovic N, Niebrzydowski J, et al. A randomized, double-blind, part III research evaluating SB2, an infliximab biosimilar, to the infliximab reference product remicade in sufferers with average to extreme rheumatoid arthritis regardless of methotrexate remedy. Ann Rheum Dis. 2017;76(1):58–64. https://doi.org/10.1136/annrheumdis-2015-207764
Emery P, Vencovský J, Sylwestrzak A, et al. A part III randomized, double-blind, parallel-group research evaluating SB4 with etanercept reference product in sufferers with energetic rheumatoid arthritis regardless of methotrexate remedy. Ann Rheum Dis. 2017;76(1):51–7. https://doi.org/10.1136/annrheumdis-2015-207588
Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR suggestions for the administration of rheumatoid arthritis with artificial and organic disease-modifying antirheumatic medication: 2019 replace. Ann Rheum Dis. 2020;79(6):685–99. https://doi.org/10.1136/annrheumdis-2019-216655
Trotta MC, Alfano R, Cuomo G, et al. Comparability of timing to develop anti-drug antibodies to Infliximab and Adalimumab between Grownup and Pediatric Age Teams, Males and Females. J Pediatr Pharmacol Ther. 2022;27(1):63–71. https://doi.org/10.5863/1551-6776-27.1.63
Melo AT, Campanilho-Marques R, Fonseca JE. Golimumab (anti-TNF monoclonal antibody): the place we stand as we speak. Hum Vaccin Immunother. 2021;17(6):1586–98. https://doi.org/10.1080/21645515.2020.1836919
Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: affect on medical efficacy and tolerability within the administration of Autoimmune Illnesses. A scientific assessment and Meta-analysis. BioDrugs. 2015;29(4):241–58. https://doi.org/10.1007/s40259-015-0134-5
Kishimoto TK, Maldonado RA. Nanoparticles for the induction of Antigen-Particular Immunological Tolerance. Entrance Immunol. 2018;9:230. https://doi.org/10.3389/fimmu.2018.00230. Revealed 2018 Feb 20.
Chen SY, Xu XX, Li X, et al. Latest advances within the intracellular supply of macromolecule therapeutics. Biomater Sci. 2022;10(23):6642–55. https://doi.org/10.1039/d2bm01348g. Revealed 2022 Nov 22.
Patel S, Kim J, Herrera M, Mukherjee A, Kabanov AV, Sahay G. Temporary replace on endocytosis of nanomedicines. Adv Drug Deliv Rev. 2019;144:90–111. https://doi.org/10.1016/j.addr.2019.08.004
Farhangian ME, Feldman SR. Immunogenicity of biologic therapies for psoriasis: therapeutic penalties and the potential worth of concomitant methotrexate. Am J Clin Dermatol. 2015;16(4):285–94. https://doi.org/10.1007/s40257-015-0131-y
Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in beforehand handled HER2-Optimistic breast Most cancers. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510
Eskandari Z, Bahadori F, Celik B, Onyuksel H. Focused Nanomedicines for Most cancers Remedy, from fundamentals to medical trials. J Pharm Pharm Sci. 2020;23(1):132–57. https://doi.org/10.18433/jpps30583
Gargett T, Abbas MN, Rolan P, et al. Section I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma. Most cancers Immunol Immunother. 2018;67(9):1461–72. https://doi.org/10.1007/s00262-018-2207-z
Sikder S, Gote V, Alshamrani M, Sicotte J, Pal D. Lengthy-term supply of protein and peptide therapeutics for most cancers therapies. Professional Opin Drug Deliv. 2019;16(10):1113–31. https://doi.org/10.1080/17425247.2019.1662785
Mellor RD, Uchegbu IF. Ultrasmall-in-Nano: why dimension issues. Nanomaterials (Basel). 2022;12(14):2476. https://doi.org/10.3390/nano12142476. Revealed 2022 Jul 19.
Duan X, Li Y. Physicochemical traits of nanoparticles have an effect on circulation, biodistribution, mobile internalization, and trafficking. Small. 2013;9(9–10):1521–32. https://doi.org/10.1002/smll.201201390
Genito CJ, Batty CJ, Bachelder EM, Ainslie KM. Issues for dimension, Floor Cost, Polymer Degradation, Co-Supply, and Manufacturability within the growth of Polymeric particle vaccines for infectious Illnesses. Adv Nanobiomed Res. 2021;1(3):2000041. https://doi.org/10.1002/anbr.202000041
Liu Y, Yang G, Jin S, Xu L, Zhao CX. Improvement of high-drug-loading nanoparticles. ChemPlusChem. 2020;85(9):2143–57. https://doi.org/10.1002/cplu.202000496
